title: Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion.
abstract: OBJECTIVE
  To determine early evolution of the vitreomacular interface and clinical efficacy and safety profile after ocriplasmin treatment.
  
  
  METHODS
  Retrospective, multicenter, observational case series. Patients with vitreomacular adhesion (VMA) confirmed on optical coherence tomography (OCT) received a single intravitreal ocriplasmin injection. Changes in the vitreomacular interface were evaluated by spectral-domain OCT. Adverse events were monitored at all visits.
  
  
  RESULTS
  Of 22 patients treated with ocriplasmin, 14 (64%) had VMA resolution, with six (43%) achieving VMA release within the first week. Eight patients (36%) showed improvement in visual acuity (VA) of at least two Snellen lines. Rate of VMA resolution was 79% for VA less than 20/40 and 38% for VA of 20/40 or greater. Safety findings include changes in the ellipsoid layer (n = 3) and transient increases in subretinal fluid (n = 6).
  
  
  CONCLUSIONS
  Ocriplasmin was effective for VMA resolution, with a rapid onset of action. Patients with worse baseline VA showed a higher VMA resolution rate.
authors.forename: Jacob C
authors.initials: JC
authors.lastname: Meyer
authors.forename: Gaurav K
authors.initials: GK
authors.lastname: Shah
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Blinder
authors.forename: Nadia K
authors.initials: NK
authors.lastname: Waheed
authors.forename: Elias
authors.initials: E
authors.lastname: Reichel
authors.forename: Peter
authors.initials: P
authors.lastname: Stalmans
authors.forename: Michael
authors.initials: M
authors.lastname: Singer
authors.forename: Asheesh
authors.initials: A
authors.lastname: Tewari
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005128:Eye Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D000267:Tissue Adhesions / Q000188:drug therapy / Q000473:pathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin